| Literature DB >> 12182948 |
Ingrid Fruitier-Arnaudin1, Marie Cohen, Stéphanie Bordenave, Frédéric Sannier, Jean-Marie Piot.
Abstract
The role of angiotensin IV (AngIV) in the regulation of angiotensin-converting enzyme (ACE) was studied in vitro. This study demonstrates that this active fragment appeared as a novel endogenous ACE inhibitor. Inhibitory kinetic studies revealed that AngIV acts as a purely competitive inhibitor with a K(i) value of 35 microM. AngIV was found to be quite resistant to ACE hydrolysis opposite to hemorphins which are both ACE inhibitors and substrates. In order to confirm a putative role of AngIV and hemorphins in the Renin-Angiotensin system (RAS) regulation, we studied their influence on AngI conversion. We noticed that 16.7 microM of both peptides decreased more than 50% of AngI conversion to AngII in vitro. The capacity of hemorphins, particularly LVVH-7, and AngIV to inhibit ACE activity here suggests a synergistic relation between these two peptides and the regulation of RAS. Copyright 2002 Elsevier Science Inc.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12182948 DOI: 10.1016/s0196-9781(02)00083-9
Source DB: PubMed Journal: Peptides ISSN: 0196-9781 Impact factor: 3.750